Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) — shareholding pattern, promoter holding, financials and share price
About Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG)
Vaidya Sane Ayurved Laboratories Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as MADHAVBAUG and on the BSE under scrip code 535434. Its ISIN is INE0JR301013.
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running of hospitals & clinics, and sale of Ayurved based medicines [1]
Vaidya Sane Ayurved Laboratories Limited (Madhavbaug) specializes in integrative Ayurvedic healthcare, focusing on disease reversal for cardiac issues, diabetes, hypertension, and obesity through its extensive clinic network and hospitals.
Recent half-year financials reflected robust growth, with a 19.48% increase in revenue compared to the prior year, driven by enhanced patient engagement and a strategic shift towards disease reversal programs.
Listed peers in Healthcare Service Provider: Star Imaging and Path Lab Ltd, Vijaypd Ceutical Ltd, Nephro Care India Ltd, Aspira Pathlab & Diagnostics Ltd, Invicta Diagnostic Ltd, Choksi Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹183.9 a share on 10 Jul 2026, Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) was valued at a price-to-earnings ratio of 21.51x against an industry P/E of 61.73x and a price-to-book of 2.21x on a book value of ₹83.16 per share. Solomo computes return on equity of 10.28% and return on capital employed of 12.74% from filed results.
- P/E
- 21.51x
- Industry P/E
- 61.73x
- P/B
- 2.21x
- EPS (TTM)
- ₹5.81
- Book value / share
- ₹83.16
- ROE
- 10.28%
- ROCE
- 12.74%
- ROA
- 8.6%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- 16.63%
- 52-week range
- ₹150 – ₹335
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) reported revenue of ₹107 crore, net profit of ₹9 crore and earnings per share of ₹8.55. That compares with revenue of ₹90 crore and net profit of ₹7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹57 crore and net profit ₹4 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 99 | 99 | 90 | 107 |
| Net profit (₹ cr) | 5 | 2 | 7 | 9 |
| EPS (₹) | 4.59 | 1.88 | 6.8 | 8.55 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 2.98% | 5.25% | -9.54% |
| Profit growth | - | 12.18% | 259.30% |
| Stock price CAGR | - | -15% | 14% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 66.34% of Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) (unchanged from the previous quarter). Market capitalisation was ₹193 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2022.
Largest disclosed public shareholders in Mar 2026: THERMO PADS PRIVATE LIMITED 2.88%, VIRTUOUS CAPITAL LIMITED 2.28%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 66.34% | - | - | - | - |
| Dec 2025 | 66.34% | - | - | - | - |
| Sep 2025 | 66.34% | - | - | - | - |
| Mar 2025 | 66.34% | - | - | - | - |
| Sep 2024 | 66.34% | - | - | - | - |
| Mar 2024 | 66.34% | - | - | - | - |
| Dec 2023 | 66.34% | - | - | - | - |
| Sep 2023 | 66.34% | - | - | - | - |